Gamma-aminobutyric acid type A receptor alpha-1 beta-x gamma-2 (GABAAR α1βxγ2)

The Gamma-aminobutyric acid type A receptor alpha-1 beta-x gamma-2 is a pentameric ligand-gated ion channel and the most abundant GABA-A receptor subtype in the adult mammalian brain [1, 4]. It is typically composed of two alpha-1 subunits, two beta subunits (most commonly beta-2 or beta-3), and one gamma-2 subunit, which together form a central pore selective for chloride ions [2, 5]. This receptor mediates fast inhibitory neurotransmission, known as phasic inhibition, by hyperpolarizing the postsynaptic membrane in response to the binding of the neurotransmitter GABA [1, 11]. It is a major pharmacological target for sedative-hypnotics, anticonvulsants, and anxiolytics, including benzodiazepines and non-benzodiazepine 'Z-drugs' like zolpidem [3, 6]. The alpha-1 subunit specifically confers sensitivity to the sedative and anticonvulsant effects of these modulators, while mutations in its encoding gene, GABRA1, are associated with various idiopathic generalized epilepsies [7, 12]. Therapeutic challenges include the development of tolerance and physical dependence, as well as side effects such as ataxia and cognitive impairment [8, 11]. This subtype is also involved in the anesthetic effects of drugs like propofol and etomidate [3, 11]. Overall, the alpha-1 containing GABA-A receptor is a critical component of the brain's inhibitory system and a primary focus for drug development in neurology and psychiatry [1, 8].

Other names

alpha1-containing GABA-A receptorBZ1 receptorBenzodiazepine receptor type 1GABRA1-containing GABA-A receptor

Positive allosteric modulation of the GABA-A receptor, specifically increasing the frequency of chloride channel opening in response to GABA binding at the alpha-gamma subunit interface [2, 8].